Matinas BioPharma Inc. is a privately-held biopharmaceutical company focused on the development of omega-3-based prescription therapeutics for the treatment of metabolic and cardiovascular conditions. Matinas is building on the extensive and proprietary research and development capabilities of its founding management team. The Matinas BioPharma team brings a cumulative multi-decade omega-3 pharmaceutical development and commercialization experience to the Company, providing a unique perspective and capability for creating the next generation of omega-3-fatty-acid-based pharmaceutical products.
The newest scientific discoveries demonstrate that essential fatty acids are not just metabolic substrates or structural building blocks, but they also directly act on nuclear receptors and are part of gene expression regulatory mechanisms. Each long chain fatty acid appears to have its own role in regulating human physiology through certain metabolic pathways.
The advancements in the field of medicinal lipidology provided the impetus and foundation in designing Matinas BioPharma’s lead product MAT9001. Matinas BioPharma is developing MAT9001 for therapeutic applications in the dyslipidemia field. Led by a dynamic and experience management team, Matinas BioPharma, with MAT9001, is poised to capitalize on these novel advancements.